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Abstract 
The immunomodulatory drug fingolimod (FTY720, GilenyaR) was approved for oral treatment 
of relapsing-remitting multiple sclerosis, due to its impressive efficacy and good tolerability. 
Pharmacologically, it acts as an unselective agonist of sphingosine 1-phosphate receptors 
(S1PR) and as a selective functional antagonist of the S1P1 subtype by induction of receptor 
downregulation. Since S1P1 is crucial for the regulation of lymphocyte trafficking, its 
downregulation causes redistribution of the immune cells to secondary lymphoid tissues, 
resulting in the depletion from the circulation and hence immunosuppression. Numerous 
preclinical studies have since been performed with the aim to increase the spectrum of 
potential indications for fingolimod with emphasis on other autoimmune disorders and 
diseases associated with inflammation and uncontrolled cell proliferation, including cancer. 
As an alternative to fingolimod, novel S1PR modulators with a more selective receptor 
activation profile and improved pharmacokinetic performance and tolerability have also been 
developed. Preclinical and clinical studies are ongoing to investigate their therapeutic 
potential for various indications. This review discusses the most relevant preclinical and 
clinical findings from S1PR-targeting and from less-well defined off-target effects reported in 
the literature, and reveals perspectives for using fingolimod and functionally-related 
derivatives and new formulations in the management of an increasing number of diseases. 
 
Keywords: Fingolimod, S1P receptor modulators, preclinical developments, pharmacology, 
clinical indications, adverse events 
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List of abbreviations: 
ALS, amyotrophic lateral sclerosis; BDNF, brain-derived neurotropic factor; CerS, ceramide 
synthase; CNS, central nervous system; CPL, cecal ligation and puncture; cPLA2, cytosolic 
phospholipase A2; CSA, cyclosporine; CTL, cytotoxic T lymphocytes; CYP450, cytochrome 
P450; DAMPs, damage-associated molecular patterns; EAE, experimental autoimmune 
encephalomyelitis; ERK, extracellular signal-regulated protein kinase; FTY720, fingolimod; 
HDAC, histone deacetylase; HDL, high density lipoprotein; ISP-1, myriocin; KO, knockout; 
LPA, lysophosphatidic acid; LPP3, lysophospholipid phosphatase 3; MECP2, methyl-CpG-
binding protein 2; MMF, mycofenolate mofetil; MS, multiple sclerosis; NK, natural killer cells; 
PECAM, platelet endothelial cell adhesion molecule; PP2A, protein phosphatase 2A; PPMS, 
primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, 
secondary progressive multiple sclerosis; SphK, sphingosine kinase; S1P, sphingosine 1-
phosphate; Sgpl1, S1P lyase; SIRS, systemic inflammatory response syndrome; SLE, 
systemic lupus erythematosus; SPP1, S1P phosphatase 1; T1D, type 1 diabetes mellitus; 
T2D, type 2 diabetes mellitus; Th, T helper cell; TLR, Toll-like receptor; TNBS, 
trinitrobenzene sulfonic acid; TRPM7, transient receptor potential cation channel M member 
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1. Historic development of fingolimod 
Fingolimod (FTY720, GilenyaR, 2-amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol) was 
originally synthesized by the Japanese chemist Tetsuro Fujita from Yoshitomi 
Pharmaceutical Industries Ltd. (present Mitsubishi Tanabe Pharma Corporation, Japan) 
(Adachi et al., 1995) using the natural compound myriocin (ISP-1) as a lead. Myriocin was 
previously isolated by the same group from the culture broth of Isaria sinclairii, the imperfect 
or asexual stage of the genus Cordyceps sinclarii (cordycipitaceae), a subfamily of parasitic 
fungi. It was described as an immunosuppressant 10-100 times more potent than cyclosporin 
A (Chiba et al., 1998; Fujita et al., 1996). Remarkably, extract and powder from the near 
relative Cordyceps sinensis has been widely used in Traditional Chinese Medicine due to its 
energy boosting effect and to grant eternal youth. Based on the chemical structure of 
myriocin, a series of derivatives were synthesized from which FTY720 turned out to be an 
even more potent immunosuppressant when tested in vitro in a mouse allogenic mixed 
lymphocyte reaction assay, and in vivo in rat and dog transplantation models where allograft 
survival was prolonged for several weeks (Chiba et al., 1998; Fujita et al., 1996; Suzuki et al., 
1996b). 
 
2. Mechanism of action of fingolimod 
The main immunomodulatory mechanism of action of fingolimod is based on its effect on 
lymphocyte homing. It reversibly redistributes T and B cells from the circulation to secondary 
lymphoid organs like peripheral and mesenteric lymph nodes and Peyer's patches, thereby 
causing a state of peripheral lymphopenia (Chiba et al., 1998). Since fingolimod resembles in 
chemical structure the sphingolipid molecule sphingosine, it can serve as a substrate for 
sphingosine kinase (SphK) to become phosphorylated to the active metabolite fingolimod-P 
(Brinkmann et al., 2002). Thus, fingolimod is a pro-drug which requires SphK to become 
active. Two subtypes of SphK, SphK1 and SphK2, exist and in principle both enzymes can 
phosphorylate fingolimod in vitro (Billich et al., 2003). However, SphK2 is 30-fold more 
efficient due to a lower Km value of fingolimod for SphK2 compared to SphK1 (Billich et al., 
2003). Furthermore, SphK2 is the only enzyme which activates fingolimod in vivo, since only 
Sphk2 knockout mice are resistant to fingolimod-induced lymphopenia (Zemann et al., 2006) 
and lack fingolimod-mediated protection from disease symptoms in experimental 
autoimmune encephalomyelitis (EAE), a widely used animal model for multiple sclerosis 
(Imeri et al., 2016).  
Fingolimod-P mimics sphingosine 1-phosphate (S1P) in structure and thus, not surprisingly, 
also binds to S1P receptors (Brinkmann et al., 2002) (Mandala et al., 2002). S1P receptors 
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were originally described as endothelial differentiation genes (edg) and build a subclass of G 
protein-coupled lipid receptors, which are most homologous to the lysophosphatidic acid 
(LPA) receptors. So far, 5 subtypes of S1P receptors have been identified, denoted S1P1-5. 
They have all been determined to bind S1P with high affinity (Kihara et al., 2014) with binding 
constants ranging from 1 to 10 nM, except for S1P4, which has a ten-fold lower affinity 
(Mandala et al., 2002). Fingolimod-P binds with similar affinity as S1P to S1P1, S1P3, and 
S1P5, but shows much better binding to S1P4 than S1P (6 nM versus 90 nM) (Mandala et al., 
2002). Fingolimod is not a ligand for S1P2 . 
Due to the diversity of S1P receptor subtypes with their distinct function and ubiquitous 
expression in the body (Kihara et al., 2014; O'Sullivan et al., 2017), in theory multiple effects 
can be expected from using fingolimod, which may either have therapeutic benefit or cause 
adverse events. 
 
3. Specific Fingolimod targets 
3.1. The S1P receptor family 
The S1P1 receptor 
As outlined above and because of its binding to and activation of the various S1P receptor 
subtypes, except for S1P2, „active“ fingolimod is pharmacologically considered an 
unselective S1P receptor agonist (Brinkmann, 2007; Brinkmann et al., 2002; Mandala et al., 
2002). Moreover, it causes sustained desensitization of the S1P1-mediated signaling 
pathway by inducing receptor internalization and degradation, which on the cellular level 
results in functional antagonism. This effect of fingolimod on S1P1 is unique and not seen 
with the endogenous ligand S1P, which also internalizes S1P1 upon binding but then 
dissociates in endosomes and the receptor recycles back to the plasma membrane. 
Similarly, S1P3,4, and 5 are also internalized upon fingolimod-P binding and then redistribute 
back to the cell surface. Particularly, downregulation of S1P1 on T cells is supposed to 
account for the immunosuppressive effect of fingolimod, whereas downregulation of S1P1 in 
other cell types, notably in endothelial cells, is likely responsible for the adverse events 
observed under long-term fingolimod treatment (Brinkmann, 2007). The agonistic effect of 
fingolimod on S1P3,4 and 5 may account for additional biological effects with unknown 
consequences as outlined below. 
These early pioneering studies have fueled research on S1P1 receptor biology to better 
understand its role in human diseases. Since S1P1 is ubiquitously expressed in almost every 
cell type, its downregulation by prolonged fingolimod treatment is expected to have multiple 
consequences on cellular responses and tissue homeostasis. The generation of systemic 
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S1pr1 knockout mice corroborated the vital biological function of S1P1, since embryos die in 
the developmental stage of day E12.5-E14.5, due to impaired vessel maturation and 
hemorrhagic bleedings. 
Besides its role in immune cell trafficking and vascular development, S1P1 is implicated in the 
regulation of vascular integrity. Increased vascular permeability is a typical feature of 
inflammation and allergy, and therefore a possible barrier protective effect of S1P signaling is 
of therapeutic interest. Various in vitro and in vivo studies have investigated the effect of S1P 
and fingolimod on the endothelial barrier function. It was shown that endotoxin-induced 
microvascular permeability and inflammation leading to acute lung and kidney injury in mice 
can be reduced by direct application of either S1P or fingolimod (Peng et al., 2004). On the 
contrary, application of a S1P1 receptor antagonist (W146), induced loss of capillary integrity 
in mouse skin and lung (Sanna et al., 2006), and the most recently developed potent S1P1 
selective antagonist NIBR-0213 induced transient lung and heart permeability defects in rats, 
which promoted chronic inflammatory remodeling (Bigaud et al., 2016). Furthermore, a 
conditional gene deletion approach was used to demonstrate that plasma S1P is crucial for 
vascular integrity. Since Sphk1/Sphk2 double knockout mice are embryonically lethal, a 
conditional double knockout (KO) mouse was generated, which contains one conditional 
Sphk1 allele and one null Sphk1 allele in a Sphk2 null background (Sphkf/- Sphk2-/-) and 
carries a Cre transgene. By inducing Cre, plasma S1P levels became undetectable. These 
„pS1Pless“ mice showed a several-fold increased vascular leakage and reduced survival 
compared to wildtype mice upon administration of platelet activating factor (PAF), and the 
symptoms could be relieved by injection of a selective S1P1 agonist (AUY954) (Camerer et 
al., 2009).  
Improved endothelial barrier function resulting from S1P1 activation by S1P and fingolimod 
was also demonstrated in cultures of human endothelial cells in vitro  (Dudek et al., 2007). 
The molecular mechanisms underlying the barrier enhancing effect are not yet fully 
understood, but the role of adherens junction molecules, such as VE-cadherin and platelet-
endothelial cell adhesion molecule (PECAM-1), appears to be crucial. In this regard, it was 
shown that S1P and fingolimod-P can stimulate the translocation of VE-cadherin to cell-cell 
contact sites of endothelial cells in cultures (Sanchez et al., 2003), and in vivo in S1pr1 
knockout mice the retinal vasculature lost VE-cadherin staining (Gaengel et al., 2012). For 
PECAM-1, upregulation was detected in endothelial cells overexpressing SK-1, which is 
supposed to increase S1P levels (Limaye et al., 2005). Furthermore, S1P1 silencing was 
shown to reduce expression of PECAM-1 and VE-cadherin (Krump-Konvalinkova et al., 
2005), and deregulation of these adherens junction molecules by fingolimod was also seen in 
a mouse model of multiple sclerosis, i.e. EAE (Imeri et al., 2016). On the other hand, the 
barrier enhancing effect of fingolimod seems to be dose-dependent, since higher 
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concentrations in the range of 10 to 100 M in cultures of human umbilical vein endothelial 
cells rather compromised the barrier function, and in vivo in mechanically ventilated mice 
even aggravated lung injury (Muller et al., 2011). Similarly, in a bleomycin-induced lung injury 
model in mice, prolonged exposure to fingolimod resulted in vascular leak, fibrosis and 
increased mortality (Shea et al., 2010). 
Altogether, these studies suggest that S1P1 activation improves the endothelial barrier 
function, whereas S1P1 antagonism, notably also by prolonged fingolimod treatment, disrupts 
it, thereby increasing permeability and vascular leakage. 
 
The S1P3 receptor 
A more detailed characterization of S1P3 activation by fingolimod-P showed that it has an 
EC50 value of 7 to 10 nM for S1P3, which is comparable to the endogeneous ligand S1P. 
However, its efficacy reached only 50% of S1P, suggesting a partial agonistic effect (Riddy et 
al., 2012). By definition, a partial agonist in the presence of a full agonist produces an 
antagonistic output. This could mean that in vivo, fingolimod can also antagonize S1P3 
signaling rather than stimulate it, depending on the local S1P concentration. This idea is 
appealing and warrants further investigation, particularly in view of the potential anti-tumor 
activity of fingolimod discussed in chapter 5.3. In this context it is noteworthy that S1P3 was 
recently shown to have prometastatic properties in breast and lung carcinoma cells 
(Filipenko et al., 2016; Zhang et al., 2013), and high expression is frequently found in tumors 
from breast cancer patients where it correlates with poor prognosis (Watson et al., 2010). 
Since plasma S1P levels are often elevated in cancer patients (Alberg et al., 2013; Sutphen 
et al., 2004; Zhang et al., 2015), the requirements for fingolimod to act as a partial S1P3 
agonist and thus impede metastatic growth might be fulfilled.  
 
The S1P4 receptor 
The role of S1P4 in physiological processes is still poorly understood and therefore effects of 
fingolimod mediated by S1P4 are unclear. S1P and fingolimod-P associate with S1P4 with 
binding constants of 95 nM and 6 nM, respectively, which means that fingolimod is a much 
better ligand for this receptor than the endogenous ligand (Mandala et al., 2002). S1P4 
expression is restricted in the body and mainly found in lymphocytes and tissues of the 
immune and hematopoietic system (Graler et al., 1998).  
Knockout of S1pr4 in mice and zebrafish consistently revealed a reduction of the number of 
circulating neutrophils, suggesting a role for S1P4 in immunity and infection (Allende et al., 
2011; Pankratz, 2016). S1pr4 deficient mice also show differential reactions to inflammation 
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with exacerbated T helper (Th)2 cell responses and decreased responses of Th1 cells 
(Allende et al., 2011). Moreover, megakaryocytes generated from S1pr4 deficient mice 
showed atypical and reduced formation of proplatelets in vitro, and the recovery of platelet 
numbers after experimental thrombocytopenia was significantly delayed, suggesting a role 
for S1P4 in thrombopoiesis (Golfier et al., 2010). Of note, in humans, a rare missense variant 
of S1P4 (Arg365Leu) was reported, which generates a loss-of-function receptor and is 
associated with reduced white blood cells and neutrophil counts (Pankratz, 2016), thus 
corroborating the preclinical data from mice (Allende et al., 2011). 
 
The S1P5 receptor 
The S1P5 receptor was originally cloned as rat nerve growth factor-regulated G protein-
coupled receptor Nrg-1(Glickman et al., 1999) and later found to be identical to S1P5/edg8. It 
is predominantly expressed in the brain and spleen (Im et al., 2000; Malek et al., 2001), and 
in these tissues, it is further concentrated in oligodendrocytes and natural killer (NK) cells 
(O'Sullivan et al., 2017).  
Fingolimod-P and S1P bind to S1P5 with equally high affinity. In oligodendrocytes this 
triggers two distinct functional responses depending on the developmental stage of the cells. 
It leads to retraction in pre-oligodendrocytes, whereas it increases the survival of mature 
cells (Jaillard et al., 2005). In addition, migration of oligodendrocyte precursor cells (OPCs), 
which normally migrate over considerable distances during brain development, is inhibited by 
S1P5 activation (Novgorodov et al., 2007). Fingolimod was also shown to protect human 
oligodendrocytes from apoptosis induced by serum and glucose deprivation, suggesting a 
neuroprotective effect by activating S1P5 (Miron et al., 2008). Moreover, S1P5 is also 
expressed on brain microcapillary endothelial cells where it contributes to the blood-brain 
barrier function and maintains the immunoquiescent state of brain endothelial cells (van 
Doorn et al., 2012). 
In S1pr5 knockout mice the number of circulating NK cells is decreased (Walzer et al., 2007) 
proposing a function of S1P5 is to promoting NK cell egress  from bone marrow and lymph 
nodes into the blood, and recruiting them to sites of inflammation (Jenne et al., 2009; Walzer 
et al., 2007). S1pr5 knockout mice also lack circulating Ly6C-negative peripheral monocytes, 
but maintain normal levels in the bone marrow (Debien et al., 2013). 
 
3.2. Other targets of Fingolimod 
Besides S1P receptors, which are activated by fingolimod at low nM concentrations, other 
intracellular targets of either fingolimod or fingolimod-P have been described. These include 
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SphK1, S1P lyase (Sgpl1), ceramide synthase (CerS) 2, histone deacetyases (HDACs), 
cytosolic phospholipase A2, protein phosphatase A2 (PP2A), and the cation channel TRPM7. 
However, these off-targets respond only at much higher concentrations in the µM range. It 
was recently reported that fingolimod can in principle accumulate to high M concentrations 
in cells in vitro to achieve concentrations required for such “off-target” effects (Schroder et 
al., 2015). However, it is unlikely and evidence has never been provided that passive tissue 
targeting of fingolimod occurs in vivo. Moreover, the low target selectivity of fingolimod at 
such high concentrations is not appropriate for therapeutic use. 
 
SphK1 
As determined in vitro, fingolimod is a substrate of SphK-2 and is also phosphorylated by 
SphK-1, but with much lower efficiency (Billich et al., 2003). In vivo, however, SphK2 is the 
only kinase which activates fingolimod as demonstrated in Sphk1-and Sphk2-deficient mice. 
fingolimod, but not fingolimod-P, acts also as a direct inhibitor of SphK1, but very high 
concentrations of 50 M are needed to achieve 50% inhibition (Tonelli et al., 2010; Vessey et 
al., 2007). As a pharmacological target with oncogenic potential, SphK1 is of interest for 
cancer therapy (see chapter 5.3.). Considering the toxicity profile of fingolimod at 0.5 mg per 
day in patients (Table 2), however, it is unrealistic to believe that such high doses can be 
tolerated. Nevertheless, numerous preclinical studies have shown pro-apoptotic and anti-
tumor effects of fingolimod with tumor cell lines in vitro and in tumor models in mice, which 
could be partly attributed to inhibition of SphK1 (Pchejetski et al., 2010). 
 
S1P lyase  
S1P lyase (Sgpl1) irreversibly degrades S1P to hexadecenal and phosphoethanolamine as 
the final step for eliminating sphingolipids in the cell in addition to secretion. In contrast to 
S1P, fingolimod is not a substrate for Sgpl1 and was even shown to inhibit it (Bandhuvula et 
al., 2005). Moreover, treatment of mice with fingolimod inhibits tissue Sgpl1 within 12 h, 
resulting in stable or even increased S1P levels. It was therefore proposed that disruption of 
S1P metabolism by inhibiting Sgpl1 accounts for some of the effects of fingolimod on 
immune cells (Bandhuvula et al., 2005). In support of this, inhibition of Sgpl1 using novel 
selective inhibitors can mimic the effect of fingolimod on lymphocyte homing (Bagdanoff et 
al., 2010; Weiler et al., 2014).  
 
Ceramide synthase 2 
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Ceramide synthases (CerS) comprise a family of enzymes that acylate dihydrosphingosine to 
dihydroceramides and therefore are crucial for de-novo synthesis of ceramides (Park et al., 
2014; Wegner et al., 2016) and consequently, also the downstream metabolite S1P. Six 
subtypes of CerS have been identified which all have certain substrate preferences and 
utilize a restricted subset of fatty acid-CoAs for dihydroceramide synthesis, thereby 
generating ceramides of different chain lengths (Wegner et al., 2016). In vitro activity studies 
revealed non-competitive inhibition of CerS2 by S1P with an IC50 value of approx. 20 M 
(Laviad et al., 2008). This inhibition may represent a negative feedback regulation ensuring 
that the overproduction of cellular S1P turns off de-novo synthesis of the precursor ceramide 
and thus ensures a balanced sphingolipid homeostasis. Fingolimod, but not the 
phosphorylated form, was shown to inhibit CerS only at high concentrations in a cell-free 
assay with an IC50 value of 30 to 50 M (Lahiri et al., 2009), and also in experiments with 
human pulmonary artery endothelial cells (Berdyshev et al., 2009).  
 
Protein phosphatase 2A 
The protein phosphatase 2A (PP2A) is an important cellular Ser/Thr phosphatase that 
regulates multiple signal transduction pathways by dephosphorylating protein kinases and 
other enzymes (Millward et al., 1999). Its role as a tumor suppressor became evident for the 
first time when it was found to be strongly inhibited by the tumor promoter ocadaic acid 
(Bialojan et al., 1988). PP2A is a heterotrimeric complex built by three subunits, including a 
scaffolding subunit, a regulatory subunit and a catalytic subunit. Each subunit again exists in 
several isoforms and additional splice variants which all together allow the existence of 80 
different subforms of the PP2A holoenzyme. This finally directs its subcellular localization 
and allows for such a huge diversification of substrates. 
The first observation that PP2A is affected by sphingolipids was reported in 1993  showing 
that short-chain C2-ceramide could increase PP2A activity in vitro, whereas other 
sphingolipids such as dihydro-C2-ceramide or sphingosine had no activating effect 
(Dobrowsky et al., 1993). Later on, activity studies using the purified PP2A holoenzyme 
revealed a weak effect of fingolimod on PP2A activation in the range of a 60% increase at 10 
M, which was sufficient to inhibit Akt and induce apoptosis in leukemia cells (Matsuoka et 
al., 2003). The relevance of PP2A as a target of fingolimod in cancer therapy is discussed in 
chapter 5.3. 
 
Histone deacetylases (HDAC) 
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Histone acetylation is implicated in the epigenetic regulation of gene expression. The 
acetylation reaction is catalyzed by histone acetyltransferases (HAT) and associates with 
active gene transcription because acetylation of histones loosens the contact between core 
nucleosome proteins and DNA and facilitates the binding of transcription factors to their 
respective binding sites (Eckschlager et al., 2017; Kelly et al., 2013). On the contrary, histone 
deacetylases (HDAC) remove acetyl groups from histones, thereby tightening the chromatin 
structure, which hinders binding of transcription factors and hence suppress gene 
transcription. Numerous studies demonstrated that HDAC inhibitors have therapeutic 
potential to treat diseases such as cancer, inflammation, fibrosis and even cognitive 
disorders (Eckschlager et al., 2017; Fischer et al., 2010; Hull et al., 2016; Liu et al., 2015). 
Notably, certain HDAC inhibitors are already FDA approved and used for the treatment of 
relapsed and refractory cutaneous T-cell lymphoma (vorinostat), peripheral T cell lymphoma 
(belinostat) and multiple myeloma (panobinostat) (Eckschlager et al., 2017). Recently, it was 
reported that S1P generated by Sphk2 in the nucleus binds directly to HDAC and inhibits its 
activity. This results in hyperacetylation of histones and regulates expression of certain 
genes such as the cyclin-dependent kinase inhibitor p21 and c-fos  (Hait et al., 2009). A 
similar effect was also exerted by fingolimod-P (Hait et al., 2014) suggesting that SphK2 is a 
driver of epigenetic gene regulation.  
 
The phospholipase A2 
The phospholipase A2 (PLA2) hydrolyses phospholipids at the sn2 position and thereby 
liberates fatty acids and lysophospholipids. Particularly, the liberation of arachidonic acid, 
which serves as a precursor for all eicosanoids including prostaglandins, leukotrienes and 
thromboxane, is a crucial and rate limiting step in inflammatory reactions (Dennis et al., 
2011). PLA2 exists as a family of several subtypes subclassified as secreted low molecular 
weight enzymes (sPLA2s), cytosolic Ca
2+-dependent enzymes (cPLA2s) and Ca
2+-
independent enzymes (iPLA2s). Inhibition of sPLA2s and cPLA2 was shown to reduce 
inflammatory reactions in vitro and in vivo (Dennis et al., 2011; Kokotou et al., 2017) and the 
development of subtype specific PLA2 inhibitors as anti-inflammatory drugs and as 
alternatives to cyclooxygenase inhibitors is of great interest. In mast cells, a central cell type 
involved in inflammatory allergic disorders, fingolimod, but not fingolimod-P, inhibited 
antigen-stimulated arachidonic acid release (by 30% at 1 M) and even more potently 
prostaglandin D2 synthesis (EC50 approx. 100 nM) (Payne et al., 2007). Furthermore, in renal 
mesangial cells, which are implicated in chronic inflammatory kidney diseases like 
glomerulonephritis, fingolimod downregulated cytokine-stimulated sPLA2 production and 
secretion (Xin et al., 2007), which, however, was not due to direct inhibition but rather to 
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inhibition of a transcriptional mechanism. Thus, in addition to its immunomodulatory role, 
fingolimod has direct anti-inflammatory effects and thus potential for treating inflammatory 
and allergic diseases. 
 
The cation channel TRPM7  
Transient receptor potential cation channel subfamily M member 7 (TRPM7) is a plasma 
membrane ion channel that contains a cytosolic protein kinase domain. It has a variety of 
physiological functions, including the regulation of Ca2+ signalling, Mg2+ homeostasis, cell 
migration, proliferation and differentiation and immune responses . Inhibition or depletion of 
TRPM7 causes anoxic neuronal death, cardiac fibrosis, tumour progression and 
macrothrombocytopenia (Chubanov et al., 2017). Recently, it was shown that in HEK293 
cells overexpressing TRPM7 or in cardiac fibroblasts, TRPM7 is dose-dependently inhibited 
by fingolimod and the endogenous analog sphingosine with IC50 values of 720 nM and 300 
nM, respectively (Qin et al., 2013). No inhibition was seen by the phosphorylated species 
S1P and fingolimod-P. It was suggested that TRPM7 inhibition by fingolimod contributes to 
the drug’s anti-proliferative and anti-migratory effects (Qin et al., 2013). 
 
4. Pharmacokinetic characteristics of Fingolimod 
The pharmacokinetic characteristics of fingolimod were summarized from the report NDA 22-
527 submitted to the FDA for drug approval. A major advantage of fingolimod as a 
therapeutic agent is the possibility of its oral application. Absorption is food-independent and 
slow (maximal plasma concentration after 12-16 h), but extensive, and its bioavailability is 
high (93%). It reaches steady-state concentrations after 1-2 months during daily intake 
(Clinical Pharmacology and Biopharmaceutics Review- Application number : NDA 22-527; 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022115s0).  
Fingolimod shows high plasma protein binding (>99.7%), mainly to albumin, and in contrast 
to S1P, there is no evidence for fingolimod binding to ApoM/HDL. It has a large volume of 
distribution of approx. 20 L/kg and shows slow blood clearance (6.3±2.3 L/h), resulting in a 
half-life of 6-9 days.  
In the blood, there is a stable equilibrium between fingolimod and fingolimod-P and both 
plasma levels decrease in parallel following similar elimination kinetics. The enzymes 
involved in regulating the equilibrium between the inactive and active compound are Sphk2 
and ecto-phosphatase lysophospholipid phosphatase 3 (LPP3). It is noteworthy, however, 
that fingolimod-P can also be dephosphorylated intracellulary by the S1P phosphatase 1 
(SPP1) (Mechtcheriakova et al., 2007),  and then reenters the fingolimod blood pool. In 
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addition to phosphorylation, two further pathways of fingolimod biotransformation exist which 
are depicted in Fig. 2.  
(1) Cytochrome P450 (CYP450)-mediated -hydroxylation/oxidation followed by fatty acid-
like--oxidation steps in the liver. fingolimod blood clearance is slow with 6.3 ± 2.3 L/h. The 
main CYP450 isoform identified is CYP4F2 with only minor contributions of other CYP450 
isoforms. Inactive metabolites are then eliminated by the renal system (81%).  
(2) Fingolimod acylation by a still unknown acyltransferase to form atypical ceramides. 
Ceramides have attracted attention due to their pro-apoptotic effect on various cell types, 
and it is possible that such atypical ceramides are involved.  
The main metabolites detectable in the blood are M3 and M4 from the CYP4F2 route and 
M29 and M30 from the acylation route (Fig. 2). Quantification of the metabolites in blood 
analysis after a single oral dose of radiolabeled 14C-Fingolimod revealed that 23.3% of the 
radioactivity was bound to fingolimod, 10.3% to fingolimod-P, 8.3% to M3, 8.9% to M29 and 
7.3% to M30. 
The finding that CYP4F2 is a key enzyme in the biotransformation of fingolimod has 
prompted studies investigating the role of CYP4F2 inhibitors and possible drug interactions. 
Indeed, co-administration of the CYP4F2 inhibitor and antimycotic drug Ketoconazole was 
shown to increase the concentrations of fingolimod and fingolimod-P in the blood. Other drug 
interactions which may affect bioavailability have not been reported so far. Since fingolimod 
is metabolized mainly in the liver, dosing must be adjusted in case of liver insufficiency.   
 
5. Fingolimod as a therapeutic agent 
From its main effect to deplete peripheral lymphocytes, it is obvious that fingolimod has 
potential for the treatment of diseases associated with inappropriate immune responses, 
such as in allograft rejection and autoimmunity. First preclinical studies in rats, mice and 
dogs revealed a delay in allograft rejection with fingolimod alone and an even synergistic 
effect when used together with cyclosporine A (CSA) (Chiba et al., 1996; Suzuki et al., 
1996a). It was then tested in several phase 1 to phase 3 clinical trials (Tedesco-Silva et al., 
2004) (Mulgaonkar et al., 2006) (NCT00239811) (Tedesco-Silva et al., 2006) (Salvadori et 
al., 2006) for kidney transplantation. In the phase 3 trials, de-novo renal transplant recipients 
were randomized to receive either 5 mg fingolimod plus a reduced dose CSA, 2.5 mg 
fingolimod plus a full dose CSA or mycofenolate mofetil (MMF) plus a full dose CSA over 1 
year. Primary endpoints were incidence of acute rejection, graft loss, death or discontinuation 
of treatment. Unfortunately, these trials could not prove a superior effect of fingolimod/CSA 
treatment compared to the standard therapy with MMF/CSA, nor did fingolimod allow 
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reduction of the CSA dose. In addition, more complications were reported in the 
fingolimod/CSA groups, including decreased renal function and macula edema, leading to 
discontinuation of the studies.  
On the other hand, fingolimod could prove successful for treating multiple sclerosis, and 
under the name GilenyaR has been approved for oral treatment of RRMS. RRMS currently 
remains as the only approved indication for fingolimod, all other indications of interest are still 
under preclinical or phase 1-2 clinical investigation. 
 
5.1. Multiple sclerosis 
Multiple sclerosis (MS) is an autoimmune and chronic neurodegenerative disease that 
disrupts the normal functioning of the brain, optic nerves and spinal cord through 
inflammation-mediated white matter demyelination and axonal loss (Dutta et al., 2014; Milo 
et al., 2010). This ultimately leads to a progressive decay of both physical and cognitive 
functions. There are three main types of MS: the relapsing-remitting MS (RRMS), the primary 
progressive MS (PPMS) and the secondary progressive MS (SPMS). The transition from 
RRMS to SPMS is thought to occur when axonal loss outweighs the compensatory capacity 
of the central nervous system (CNS) such as neuroprotection and remyelination (Dutta et al., 
2014; Milo et al., 2010). 
Early on, it was recognized that fingolimod can reduce disease symptoms in various animal 
models of multiple sclerosis. These promising results prompted testing in clinical trials of 
RRMS. It is of note that for this indication fingolimod can be applied as monotherapy and at a 
ten-fold lower dose than used in the renal transplantation studies, thereby minimizing 
adverse events. Several clinical trials were performed from phase 1 to 3, where fingolimod 
proved to be effective in reducing disease symptoms and the number of relapses. In 2010, 
the FDA and EMA granted approval for this indication.  
In addition, fingolimod was tested in clinical studies for PPMS. However, the primary 
endpoint delay of MS disability progression compared to placebo, was not met. Altogether, 
fingolimod represents a clear improvement in the therapy of RRMS, mainly due to its oral 
applicability and good tolerability at clinically effective doses (Table 2). New S1PR 
modulators with higher selectivity for S1P1 or dual activity against S1P1+5 are currently under 
investigation for various other indications for which S1PR modulation represents a 
reasonable therapeutic concept (Table 3). 
 
5.2. Inflammatory bowel diseases 
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Chronic inflammatory bowel disease (IBD), which mainly includes Crohn’s disease and 
ulcerative colitis, is an idiopathic disease caused by multiple factors of genetic, inflammatory 
or environmental origin (Peyrin-Biroulet et al., 2017). The detailed mechanisms of IBD 
pathogenesis are not completely understood. It is characterized by intestinal inflammation 
and a dysregulated immune response to host intestinal microflora (Baumgart et al., 2007). 
Since T cell infiltration into the mucosa is a common feature, it is expected that fingolimod by 
redistributing immune cells to secondary lymphoid organs, can relieve disease symptoms 
and progression (Peyrin-Biroulet et al., 2017).  
First promising data with fingolimod came from a mouse model of chronic colitis. In this 
model, the disease was caused by depletion of interleukin 10 using gene knockout.  
Treatment of mice with fingolimod for 4 weeks efficiently reduced the number of CD4+ T cells 
in the colonic lamina propria and decreased the production of IFN production in colonic 
lymphocytes thereby mitigating the severity of the disease (Mizushima et al., 2004). In other 
experimental models of colitis, such as colitis induced by dextran sulfate sodium (DSS), 
trinitrobenzene sulfonic acid (TNBS) or by colitogenic T cell transfer, similar protective effects 
of fingolimod were reported (Daniel et al., 2007; Deguchi et al., 2006; Mizushima et al., 
2004). However, in other preclinical models of colitis the therapeutic effect of fingolimod 
could not be confirmed, suggesting this indication to be more critically investigated to clarify 
this inconsistency (Montrose et al., 2013; Radi et al., 2011). 
Recent data from using the new S1P1+5-selective immunomodulator ozanimod support the 
idea of targeting S1P1/5 in the treatment of IBD. In this regard, ozanimod was shown to 
decrease inflammation and disease parameters in TNBS-induced colitis and colitis induced 
by adoptive T cell transfer in mice (Scott et al., 2016). It was then further tested in a phase 2 
clinical study (NCT02435992) in patients with moderately or severe active ulcerative colitis. 
Daily oral treatment with 1 mg ozanimod achieved higher clinical response rates and 
remissions, and improved mucosal healing resulting in lower Mayo Clinic scores compared to 
placebo. This effect was already seen 8 weeks after the start of treatment and was 
maintained up to week 32 (Sandborn et al., 2016). Similarly, the new S1P1-selective agonist 
KRP-203 (2-amino-2-{2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl}-1,3-propanediol 
hydrochloride) (Fujishiro et al., 2006; Shimizu et al., 2005)  also proved to be effective in  
mitigating the symptoms of colitis (Song et al., 2008). A clinical phase 2 study 
(NCT01375179) to assess its potential in the treatment of ulcerative colitis was conducted 
but terminated early due to non-convincing results at a first interim analyses after 18 months 
(according to the company’s clinical trial results database https://www.novctrd.com/). 
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More recently, the next generation S1P1+4+5-selective modulator etrasimod (APD334) (Buzard 
et al., 2014) also entered a phase 2 study (NCT03139032) in IBD patients and it remains to 
be seen whether this compound holds more promise to reduce disease symptoms. 
 
5.3. Psoriasis 
Psoriasis is a chronic inflammatory skin disease characterized by infiltration of T cells into 
skin lesions and by focal formation of inflamed raised plaques which constantly shed scales 
derived from hyperproliferating skin epithelial cells. First-line and still the most effective 
therapy is the use of glucocorticoids, which classically act by immune suppression and by 
reducing keratinocyte proliferation (Das et al., 2009). 
In principle, fingolimod could be useful in the treatment of psoriasis by redistribution of the T 
cells away from the skin and by blocking migration of skin dendritic cells to draining lymph 
nodes where antigen presentation to naïve lymphocytes occurs (Han et al., 2015). 
Unfortunately, since animal models of psoriasis do not exist, efficacy of fingolimod has not 
been demonstrated. Nevertheless, second-generation S1PR modulators with higher 
selectivity have been developed. One is ponesimod which was tested in a phase 2 study 
(NCT01208090) in patients with moderate to severe chronic plaque psoriasis. The primary 
endpoint was defined as 75% reduction in psoriatic area after 16 weeks. The conclusion from 
the study was that treatment with ponesimod resulted in clinical responses after 16 weeks 
and symptoms improved further when it was continued (Vaclavkova et al., 2014). 
 
5.4. Rheumatoid arthritis 
Rheumatoid arthritis is another autoimmune disease that mainly affects the joints and leads 
to a progressive disability (McInnes et al., 2011). It is characterized by synovial inflammation 
and hyperplasia, autoantibody production, cartilage and bone destruction, but is also 
associated with systemic complications such as cardiovascular, pulmonary and skeletal 
disorders (McInnes et al., 2011). Reactive T cells are implicated in the pathogenesis of the 
disease and it is plausible to assume that fingolimod has therapeutic benefit. Indeed, in 
various rat and mouse models of arthritis fingolimod was shown to reduce the incidence of 
arthritis, and to reduce hindpaw swelling and bone destruction (Matsuura et al., 2000; 
Tsunemi et al., 2010; Wang et al., 2007; Yoshida et al., 2013). Clinical studies with 
fingolimod or  novel S1PR modulators in patients with arthritis have not been performed yet. 
 
5.5. Cancer 
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5.5.1. S1PR-dependent effects 
The immune suppressive effect of fingolimod results from impeding egress of naïve and 
central memory T cells from lymph nodes upon S1P1 binding of its phosphorylated analog 
fingolimod-P generated by SphK2 (Brinkmann et al., 2010; Kharel et al., 2005; Mehling et al., 
2008; Zemann et al., 2006). Whereas a decrease of circulating lymphocytes and reduced cell 
trafficking to sites of inflammation like in the CNS accounts for efficacy in MS, immune 
suppression is counterproductive in cancer patients. Even if it may affect also regulatory T 
cells implicated in downregulating anti-tumor immune responses (Wolf et al., 2009), the 
decline of circulating cytotoxic T cells (CTLs) and certain NK cells (Johnson et al., 2011) 
potentially hampers tumor rejection and immune surveillance. To overcome the 
immunosuppressive effect of fingolimod, derivatives were generated which cannot be 
phosphorylated and bind to S1P1, but still maintain biological activity in cells (Omar et al., 
2011; Segura-Ulate et al., 2017). In addition to inducing a decline in circulating immune cells 
by S1P1 binding, data from preclinical mouse models suggest that fingolimod also stimulates 
the accumulation of myeloid-derived suppressor cells in tumors via S1P3-dependent 
stimulation of GM-CSF release, which would favor immune escape and tumor growth (Li et 
al., 2017). In this context, it is noteworthy that S1P3 signaling was recently shown to have 
prometastatic properties in breast and lung carcinoma cells (Filipenko et al., 2016; Zhang et 
al., 2013). Since fingolimod-P was found to act only as a partial agonist of S1P3 with about 
50% of the activity of S1P (Riddy et al., 2012), it would be interesting to see if it has anti-
metastatic activity by antagonizing S1P3 in the presence of high levels of S1P. 
 
5.5.2. S1PR-independent effects (off-target) 
Fingolimod was shown to inhibit cancer-relevant signal transduction pathways independent 
of S1PR binding, in part due to its structural similarity to sphingosine. The heterogeneity of 
responses to fingolimod includes increased cell death, decreased cell proliferation, 
angiogenesis, migration, invasion, metastasis and inflammation (Patmanathan et al., 2015; 
White et al., 2016). Thus, by targeting multiple oncogenic signaling pathways and 
compensatory pathways implicated in drug resistance, fingolimod in principle holds promise 
for drug repurposing as an anticancer agent for various oncology indications characterized 
by different molecular abnormalities. 
The mechanisms underlying the S1PR-independent anti-tumor activity of fingolimod are less 
well defined and all were measured at relatively high µM concentrations. One of the better 
characterized effects is inhibition and proteasomal degradation of the oncoprotein SphK1 
(Tonelli et al., 2010) and hence downmodulation of various well-characterized pro-
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tumorigenic processes associated with this pathway (Lim et al., 2011; Pchejetski et al., 2010; 
Vessey et al., 2007). 
Another target of fingolimod in cancer is PP2A, a tumor suppressor with decreased activity in 
various human tumors (Cristobal et al., 2016; Grech et al., 2016; Perrotti et al., 2013). 
Inhibition of PP2A occurs by mutations, hyperphosphorylation of the catalytic subunit or 
deregulation of the endogenous inhibitors SET and CIP2A (Chen et al., 1992; Cristobal et al., 
2016; Saddoughi et al., 2013), leading to constitutive activation of survival signaling 
pathways (Pitman et al., 2012). Surface plasmon resonance (SPR) analysis indeed 
demonstrated that fingolimod binds to I2PP2A/SET with a Kd of 11 nM (Saddoughi et al., 
2013) but biological activity was again only measured at µM concentrations. Further effects 
of fingolimod on PP2A function seem to include CIP2A downregulation and PP2A 
hypophosphorylation (Rincon et al., 2015), but these mechanisms need to be explored in 
more detail. In BCL/ABL-transformed leukemia cells, 2.5 M fingolimod was shown to 
increase cellular PP2A activity by 400 % and consequently dephosphorylate and degrade 
BCR/ABL with an EC50 value of 80 nM (Neviani et al., 2007). It was suggested that this 
mechanism accounts for the anti-tumor effect in Philadelphia chromosome (Ph1)-positive 
leukemia. Fingolimod was also shown to inhibit activation of the chemokine receptor CXCR4 
in multiple myeloma. CXCR4 and its ligand CXCL12 are crucial for multiple myeloma cell 
proliferation and regulate the migration and homing to the bone marrow (Azab et al., 2009). 
The anti-leukemic effect of fingolimod occurred in cooperation with bortezomib and the 
molecular data suggest a cross-talk between the S1P and the CXCR4 pathways (Beider et 
al., 2017). However, inhibition of CXCR4 determined by analysis of intracellular survival 
signaling via extracellular signal-regulated protein kinase (ERK)1/2 and S6 proteins was 
measured at a concentration of 20 µM fingolimod without showing data from lower doses at 
which cell viability was already decreased. Anti-leukemic activity of fingolimod was also 
measured in mice, but only after daily injections of very high doses of 10 mg/kg, which 
makes it difficult to predict the clinical potential of the treatment. 
Current preclinical data suggest that a downside of fingolimod for cancer therapy is its low 
efficacy and potency. In vitro, biological responses in cancer cells were reported at µM 
concentrations, and in tumor xenograft models in mice, anti-tumor activity was always 
measured after daily injections of aberrantly high doses, ranging from 2.5-10 mg/kg (Beider 
et al., 2017; Cristobal et al., 2014; Gstalder et al., 2016; Pchejetski et al., 2010; Rincon et al., 
2015). This is up to 1400-fold more than used in patients to treat MS, and it is clear that at 
such high doses numerous targets are affected which are crucial for normal tissue function. 
The safety data for fingolimod shown for the 0.5 mg daily schedule (Table 1) make it 
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unrealistic to believe that such high doses can be applied to patients without escalation of  
toxicity. 
To improve the efficacy and tolerability of fingolimod, second-generation derivatives and 
complex pharmaceutical formulations were engineered and tested in various preclinical 
tumor models. These include the analog OSU-2S, which shows reduced S1PR modulation 
and increased inhibition of tumor cell proliferation (Omar et al., 2011), lipid-encapsulated 
ingolimod for oral delivery (Estella-Hermoso de Mendoza et al., 2015), nanoparticles 
combining fingolimod with docetaxel (Alshaker et al., 2017; Wang et al., 2017), and 
fingolimod-loaded nanocarriers targeting CD19, CD20 or CD37 (Mao et al., 2014). However, 
again, these new developments were tested at clinically unrealistic mg/kg doses and 
therefore conclusions for anti-tumor activity in patients cannot be drawn. 
Altogether, these preclinical studies reveal that very high concentration of fingolimod are 
needed to reduce cancer cell viability in vitro and affect tumor growth in xenograft models in 
vivo. At such high doses, effects of low specificity are common and indeed multiple low-
affinity targets of fingolimod have been described, increasing the risk of unpredictable 
complications. We therefore conclude that fingolimod will likely fail to achieve clinical 
responses in cancer patients at tolerable doses. 
 
5.6. Stroke 
Ischemic stroke occurs as a result of occlusion of a cerebral artery by a blood clot, which 
causes oxygen and glucose deprivation and results in neuronal death, either by apoptosis or 
necrosis, and in metabolic and functional deficits. Dying cells then release factors such as 
damage-associated molecular patterns (DAMPs) that stimulate the pathogen recognition 
receptors toll-like receptor (TLR)-2 and -4, activate NF-κB and the synthesis of various pro-
inflammatory mediators, including IL-1β, TNF-α, and chemokines. These in turn recruit 
immune cells to the affected brain area to clear cell debris and promote healing. Immune 
cells infiltrating during the first phase consist of macrophages and neutrophils, and in a 
second delayed phase of T- and B cells (Santos Samary et al., 2016). However, 
ischemia/reperfusion injury is not restricted to the brain but occurs also in other organs, and it 
was first shown that fingolimod is capable of reducing tissue injury in kidney and liver upon 
ischemia/reperfusion induction (Anselmo et al., 2002; Troncoso et al., 2001). In view of this 
finding, animal models of stroke were performed where it was demonstrated that fingolimod 
reduces lesion size and improves neurological outcome after experimental stroke (Czech et 
al., 2009). In the meantime, several more preclinical studies using fingolimod in animal 
models of stroke were reported, and a systematic review and a meta-analysis of the data 
was conducted to prove the drug’s efficiency in such animal models. Results indicated an 
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overall beneficial efficacy of fingolimod in stroke models with one negative study that used a 
permanent middle cerebral artery occlusion model (Liu et al., 2013). However, it should be 
kept in mind that animal experiments are routinely not performed in aged mice which would 
resemble the situation in humans with comorbidities like diabetes and hypertension (Liu et 
al., 2013). 
A pilot trial and a clinical phase 2 study (NCT02002390, NCT02956200) were performed to 
provide proof-of-concept for the efficacy of fingolimod, also in combination with alteplase and 
thrombectomy, to reduce brain inflammation and improve clinical outcomes of acute ischemic 
stroke in patients. The data revealed that patients treated with alteplase plus fingolimod 0.5 
mg daily for 3 consecutive days within 4.5 hours after the onset of ischemic stroke showed a 
significant reduction of neurologic impairment compared to patients in the standard therapy 
receiving group. Neurologic functions improved in these patients during the first week in 
coincidence with a reduction of circulating lymphocyte counts. After 3 months, more patients 
in the fingolimod group achieved full recovery of their neurologic capability (Fu et al., 2014; 
Zhu et al., 2015) 
 
5.7. Systemic inflammatory response syndrome /sepsis 
Systemic inflammatory response syndrome (SIRS), sepsis and septic shock are typically 
characterized by a strong inflammatory reaction and dysregulated vascular permeability, 
leading to hypovolaemia and severe tissue edema finally culminating in multiorgan failure. 
Numerous options to block the inflammatory response, i.e. by neutralizing or antagonizing 
TNF or IL-1 have been explored over years, but all failed due to the multifactorial nature 
of the disease. Moreover, hypovolaemia is normally treated by volume substitution, but due 
to the increased vascular permeability the added fluid can even aggravate edema formation. 
Therefore, likely more promising is to directly target the vascular endothelial cells and 
increase their barrier function. Since S1P1 activation is well described as a barrier enhancing 
mechanism, the activation of this receptor signaling system is desirable. Interestingly, in 
sepsis, serum levels of S1P (Coldewey et al., 2016; Frej et al., 2016; Winkler et al., 2015) 
and its carrier ApoM/HDL (Christoffersen et al., 2012; Wu et al., 2004) are downregulated, 
which further suggests the usefulness of increasing S1P/S1P1 signaling to reduce symptoms 
of sepsis. In this context it was previously reported that application of reconstituted HDL 
attenuates organ injury in a rat model of endotoxic shock (McDonald et al., 2003). Although 
not explicitly investigated, it is likely that S1P, which is coupled to HDL in the blood, accounts 
for the protective effect of HDL. Furthermore, fingolimod could prove protective also in 
preclinical models of sepsis. For instance, in an acute LPS-induced lung injury model in 
mice, symptoms were significantly relieved by applied S1P (at 1 M) or fingolimod (at 0.1 
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mg/kg) (Peng et al., 2004), and, in a cecal ligation and puncture (CLP)-induced sepsis model 
in rats, fingolimod, at 0.2 mg/kg decreased volume loss by 30% (Lundblad et al., 2013). 
Moreover, it improved LPS- and (CLP)-induced cardiac impairment in mice (Coldewey et al., 
2016), and reduced vascular and immune defects (Hemdan et al., 2016). On the other hand, 
the S1P1 agonist SEW2871, which was claimed to be selective for S1P1, but manifold less 
potent than S1P and lacking a functional antagonistic effect (Jo et al., 2005), could not 
substitute for fingolimod in a rat model of sepsis, but instead caused severe cardiac 
complications and no improvement of the vascular barrier function  (Flemming et al., 2017). 
This is probably due to low potency and  off-target effects caused by the use of higher doses. 
Collectively, more data are needed to rate the therapeutic potential of fingolimod in the 
treatment of SIRS and septic shock in patients.  
 
5.8. Chronic inflammatory kidney diseases  
Systemic lupus erythematosus:  
Systemic lupus erythematosus (SLE) is a systemic and poly-etiological autoimmune disease 
that is associated with a broad spectrum of clinical and immunologic manifestations. Early 
symptoms most frequently affect the skin and joints, whereas morbidity and mortality is 
mainly due to kidney damage  (Bai et al., 2017; Yu et al., 2017). The development of 
nephritis in patients with SLE involves multiple pathways including aberrant apoptosis, 
autoantibody production, immune complex deposition, complement activation and 
inflammatory cytokines and interferon- production (Bai et al., 2017; Yu et al., 2017). 
Additional typical renal features are glomerular crescents, podocyte injury, tubulointerstitial 
lesions and vascular injury. Although outcomes for patients with lupus nephritis have 
improved over the past 30 years, curative treatment of this disease still remains a challenge 
(Bai et al., 2017; Yu et al., 2017). 
Several animal models exist where the autoimmune disease spontaneously develops. Most 
commonly used are NZB/W F1, MRL-lpr/lpr and BXBS mice (Perry et al., 2011). In all three 
models, fingolimod was tested and found effective in reducing disease pathology and 
improving renal function (Alperovich et al., 2007; Ando et al., 2010; Okazaki et al., 2002).  
Notably, the novel S1P1-selective agonist KRP-203 was also tested in the MRL-lpr/lpr mice. 
When these mice received KRP-203 for 8-12 weeks, a significant reduction of kidney injury 
was observed, which was explained by its ability to block T-cell infiltration into the kidney 
(Wenderfer et al., 2008). The novel S1P1-selective cenerimod (ACT-334441) is currently 
under investigation in a phase 1 study (NCT02914223), and it will be interesting to see 
whether this compound holds the promise to mitigate disease symptoms and the progression 
of SLE. 
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Other forms of inflammatory kidney diseases: 
Fingolimod was also found effective in other inflammatory kidney diseases such as in 
mesangioproliferative glomerulonephritis or tubulointerstitial fibrosis, which have no 
autoimmune character. In rats in which chronic progressive glomerulosclerosis was induced, 
the treatment with oral fingolimod, at 0.3mg/kg daily, resulted in an effective reduction of 
blood lymphocyte counts and renal lymphocyte infiltration and proteinuria and matrix 
expansion were reduced and renal function improved (Martini et al., 2007; Peters et al., 
2004). In another study in mice, fingolimod administered orally at 1mg/kg for 5 days relieved 
tubulointerstitial fibrosis induced by unilateral ureter obstruction (Thangada et al., 2014). 
 
5.9. Atherosclerosis 
Atherosclerosis is a multifactorial disease of inflammatory nature and associated with  
increased vascular plaque formation that at some point causes rupture and thrombus 
formation. Patients therefore have a strongly increased risk for cardiovascular complications 
including coronary artery disease, myocardial infarcts and stroke (Ross, 1999). Risk factors 
for the pathogenesis of atherosclerosis include high serum levels of cholesterol/LDL, 
smoking, hypertension and diabetes mellitus (Ross, 1999). On the cellular level, 
atherosclerosis is mainly characterized by endothelial dysfunction, but other cell types are 
also involved such as macrophages, T cells and smooth muscle cells. The activated 
endothelial cells show increased permeability and adhesion of immune cells, and change 
their normally anticoagulant state into a pro-coagulant state (Dahal et al., 2017; Ross, 1999). 
In addition, the inflammatory environment stimulates proliferation and migration of vascular 
smooth-muscle cells leading to thickening and remodeling of the vascular wall (Ross, 1999). 
To date, the standard of care for this disease still aims at reducing plasma cholesterol levels 
with statins and fibrates. However, new strategies are underway to more specifically reduce 
vascular inflammation, for instance by inhibiting or neutralizing IL-1 (Ridker et al., 2017). 
Since S1P modulators like fingolimod have demonstrated anti-inflammatory potential in the 
clinical setting, their use in the treatment of atherosclerosis is suggested. 
 
Mice are resistant to atherosclerosis by nature and hence require certain genetic 
manipulations to establish suitable preclinical models. Particularly, ApoE knockout (KO) 
mice, LDL receptor KO mice, hepatic lipase KO mice or human cholesterol-ester transfer 
protein transgenic mice were shown to develop atherosclerosis with high incidence 
(Kapourchali et al., 2014).  Unfortunately, however, when fingolimod was tested in ApoE KO 
and LDL receptor KO mice under various diet conditions, outcomes were controversial and 
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difficult to explain. On the one hand, in mice kept on a cholesterol-rich diet, fingolimod 
attenuated the development of atherosclerosis, which was attributed to its effect on the 
distribution and activation of T cells and macrophages in plaques, and to reduce plasma 
cytokine levels (Keul et al., 2007; Nofer et al., 2007). On the other hand, in ApoE KO mice 
kept under standard diet (Klingenberg et al., 2007), and in LDL receptor KO mice fed with a 
low cholesterol Western-like diet (0.25%) (Poti et al., 2012), two procedures causing milder 
hypercholesterolaemia, smaller lesions and no increase of plasma cytokines, fingolimod 
could not prevent atherosclerotic lesions, although lymphocyte counts were reduced. The 
conflicting data of the studies were discussed (Poti et al., 2012), and it was proposed that 
fingolimod may be protective only under conditions of massively increased cholesterol 
burden and exacerbated inflammation. In another study, the S1P1 agonist KRP-203 also 
improved atherosclerosis lesions in LDL-R-deficient mice fed a cholesterol-rich diet (Poti et 
al., 2013), but because of these controversial findings it remains unclear whether clinical 
studies with S1PR modulators in atherosclerosis are warranted. 
 
5.10. Diabetes mellitus 
Two types of diabetes mellitus exist of which type 1 (T1D) has a juvenile onset and accounts 
for 10% of all cases of diabetes. It is characterized as an autoimmune destruction of 
pancreatic beta-cells in the islets of Langerhans. Consequently, there is a loss of insulin 
secretion and the main therapeutic option is to substitute insulin by administration. In 
contrast, type 2 diabetes (T2D) has a adult onset and covers 90% of diabetics. It is mainly 
characterized by the development of insulin resistance in peripheral tissues, and obesity and 
associated inflammation are the prevalent risk factors (Ng et al., 2017). In T2D, there is no 
evidence for autoimmune-mediated destruction of beta-cells, although amyloid deposition in 
the islets frequently occurs which may interfere with beta-cell function and insulin secretion. 
Beta-cell apoptosis: Since apoptosis of beta-cells is crucial in the development of T1D, 
understanding the regulation of apoptosis in this cell type is mandatory. The trigger for beta-
cell death comes from auto-reactive T cells that are directed against multiple islet antigens, 
and therefore, therapeutic interference with the activated immune cells seems promising. 
Several immunomodulatory drugs, including anti-CD3, anti-CD20, and CTLA4-Ig, were 
tested in clinical trials of new-onset T1D patients (Orban et al., 2011; Pescovitz et al., 2009; 
Sherry et al., 2011). Although these treatments resulted in short-term improvement of beta-
cell function for several months, durable improvement was not observed. This was explained 
by the low regenerative capacity of human beta-cells (Maganti et al., 2014). Fingolimod was 
so far only tested in animal models of autoimmune- and drug-induced diabetes, and in many 
of these models, it was found effective to normalize blood glucose levels and to protect islet 
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graft destruction (Fu et al., 2002; Maki et al., 2002; Suzuki et al., 1998; Tsuji et al., 2012; 
Yang et al., 2003). Interestingly, fingolimod also increased beta-cell survival and improved 
their regeneration in vivo in hyperglycemic db/db mice (Moon et al., 2013; Zhao et al., 2012). 
Whether fingolimod deserves further investigation in clinical trials for T1D, particularly also in 
view of disappointing long-term results with other immunomodulators, is disputable. 
Alternatively, beta-cell destruction could be impeded by targeting the molecular pathways 
involved in the death response, possibly in combination with immunomodulators like 
fingolimod. In this context, the cellular sphingolipid rheostat has attracted attention as the 
balance between pro-apoptotic ceramide and pro-survivial S1P was shown to affect the cell’s 
life/death decision. In numerous studies with beta-cells, inhibition of ceramide formation or 
stimulation of SphK1/S1P signaling could protect cells from apoptosis (Jessup et al., 2011) 
(Ng et al., 2017) (Meikle et al., 2017).  
Insulin resistance: Insulin restistance is the main risk factor for T2D. There is ample 
evidence from cell culture and animal experiments that the deregulation of ceramides, 
glucosylceramide and gangliosides is involved in insulin resistance (Chaurasia et al., 2015; 
Chavez et al., 2012). Procedures to block or deplete enzymes in the de-novo synthesis of 
ceramide, gucosylceramide synthase, or GM3 synthase, all improve glucose tolerance and 
prevent insulin resistance and diabetes (Chavez et al., 2012). Furthermore, it is was recently 
reported that adiponectin, a peptide hormone secreted by adipocytes and acting via 
adiponectin receptors (AdipoR)/AMPK to stimulate glucose uptake and fatty acid oxidation, 
has insulin-sensitizing, anti-inflammatory and anti-atherogenic activity by modulating 
ceramides.  Interestingly, AdipoR has an intrinsic ceramidase activity (Holland et al., 2011), 
and thereby, reduces cellular ceramide levels by converting it to sphingosine and further to 
the prosurvival S1P. The prosurvival effect of S1P on beta-cells was further supported by 
data from SphK1 knockout mice. When fed with high-fat diet, SphK1-deficient islets were 
more susceptible to lipotoxic stress factors (Qi et al., 2013). Fingolimod also reversed insulin 
resistance in animal models (Bruce et al., 2013; Kendall et al., 2008) and it was proposed 
that this effect was due to reduced ceramide formation in muscles (Bruce et al., 2013).  
Altogether, based on available data, fingolimod seems to have some short-term benefit in 
T1D by downregulating the immune response against beta-cell, but long-term responses are 
missing as it fails to halt disease progression. Furthermore, it must be kept in mind that in 
diabetic patients the risk for developing macula edema under fingolimod is increased (Moss, 
2017). This risk must be weighed against its rather limited benefit as an insulin sensitizer in 
diabetes. 
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5.11. Rett’s syndrome 
The Rett’s syndrome is a progressive neurodevelopmental disorder that predominantly 
affects young femals and manifests with autistic-like behavior and severe mental retardation. 
Typical symptoms include motor impairment, such as ataxia, apraxia and tremor, stereotypic 
hand movements, seizures, hyperventilation, apnea and even cardiac dysrhythmias (Cronk 
et al., 2016; Liyanage et al., 2014; Pecorelli et al., 2016). The disorder is mainly 
characterized as a genetic disease which in most cases is caused by a mutation in the X-
linked gene coding for the methyl-CpG-binding protein 2 (MECP2). In rare cases, other 
mutations, such as in the genes coding for the cyclin-dependent kinase-like 5 protein 
(CDKL5) and forkhead box G1 (FOXG1), were also described. The MECP2 protein is known 
to regulate the transcriptional activity of various genes and modulate the chromatin structure 
(Liyanage et al., 2014). A more global function as genome-wide epigenetic modulator has 
also been proposed (Liyanage et al., 2014). A well described target gene of MECP2 is the 
brain-derived neurotropic factor (BDNF) (Liyanage et al., 2014). Notably, MECP2 knockout 
mice, which represent a model for Rett syndrome and consequently develop neuronal and 
motor deficits comparable to Rett patients, showed reduced BNDF expression in various 
brain regions including hippocampus, striatum and cerebellum (Deogracias et al., 2012). In 
these mice, application of fingolimod not only increased BDNF protein expression in the 
brain, but also improved neuronal and motor deficits, and even prolonged the life-expectancy 
of the animals (Deogracias et al., 2012). Furthermore, in a rat model of valproic acid-induced 
autism, fingolimod mitigated learning and memory impairments and social deficits (Wu et al., 
2017). A phase 1 study (NCT02061137) currently investigates the safety and efficacy of 
fingolimod in children older than 6 years with Rett syndrome, and it will be interesting to see 
if fingolimod can mitigate the regression of motor and language skills. 
 
5.12. Fear extinction memory 
Since fingolimod-P was previously shown to directly inhibit HDAC activity in cell nuclei in vitro 
as well as in vivo in mouse brain (Hait et al., 2014), and in view of the finding that HDAC 
inhibitors can improve cognitive disorders (Fischer et al., 2010), it may be hypothesized that 
fingolimod can have beneficial cognitive and memory enhancing effects. In a mouse model of 
fear extinction memory testing, fingolimod application over 3 days followed by electric foot 
shock leads to a continuous reduction of the freezing time (a measure of fear towards the 
electric shock). When an extinction session was introduced after day 2 in which mice were 
reexposed to the conditioned stimulus but without footshock, they returned to a higher 
freezing time upon footshock on day 3. In contrast, fingolimod treated mice remained at the 
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low freezing time, suggesting that the extinction of aversive memories was improved (Hait et 
al., 2014). Since these experiments were carried out in immunocompromised SCID mice, 
which are deficient in both B and T cell responses, the involvement of immune-mediated 
mechanisms in the fingolimod effect was excluded, and particularly involvement of HADC 
inhibition in the hippocampus was suggested as a possible mechanism. More cognitive tests 
are needed to better rate the potential of fingolimod as enhancer of cognitive ability and 
memory. 
 
5.13. Other potential indications for fingolimod 
The above mentioned indications for fingolimod have been extensively investigated in 
preclinical studies or have already moved forward to clinical trials. In addition, fingolimod is 
under consideration for various other disorders as well, most notable are disorders 
associated with neuroinflammatory processes, such as Amyotrophic Lateral Sclerosis (ALS) 
(Potenza et al., 2016), Alzheimer (Takasugi et al., 2013), Parkinson (Zhao et al., 2017) and 
cerebral malaria (Finney et al., 2011). Currently, a clinical phase 2 study (NCT01786174) is 
ongoing to determine safety and tolerability of fingolimod in patients with ALS. It will be 
interesting to see whether it can mitigate the clinical symptoms of this still incurable 
neurodegenerative disease. 
 
6. Adverse effects of fingolimod  
Table 2 summarizes some of the adverse events reported from patients with relapsing-
remitting MS treated with low doses of 0.5 mg fingolimod daily for 24 months (FREEDOMS 
II). Those seen more frequently with fingolimod than with placebo included lymphopenia, 
increased liver transaminases, herpes viral infections, hypertension, and initial bradycardia 
and first degree AV block both as first-dose effects. Of note, analysis of pooled safety data 
from various phase 2 and phase 3 studies revealed that the risk for macular edema, which in 
FREEDOMS II occurred in 1% of the patients in both the fingolimod and the placebo group, 
was seven times more common in individuals with coexisting diabetes or history of uveitis 
when treated with 1.25 mg fingolimod (Moss, 2017; Zarbin et al., 2013). 
Also, data derived from the phase II trials on renal transplant recipients, which received 
fingolimod at 10 times higher doses and also in combination with other immunosuppressive 
drugs like CSA and MMF, additional adverse effects to the ones summarized in table 2, were 
reported including reduced lung function and renal function (Budde et al., 2006; Salvadori et 
al., 2006). 
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Here, we want to point out that based on published preclinical data much higher doses of 
fingolimod would be required to achieve anti-tumor effects in patients. To illustrate this, in 
tumor-xenografted mice doses ranging from 2.5. to 10 mg/kg daily were used, which would 
correspond to doses of 175 to 700 mg per day in cancer patients. Even though this simplified 
calculation does not fully respect differences in pharmacokinetics and drug metabolism 
between mouse and man, and between i.p. and oral delivery, considering the safety data 
shown in Table 2 for 0.5 mg fingolimod, it goes without saying that such aberrantly high 
doses will result in many more complications. 
 
Rebound syndrome upon drug discontinuation 
Fingolimod discontinuation may be necessary due to different reasons, the most common 
are severe adverse effects, breakthrough disease activity or pregnancy. In a recent study 
involving 50 patients, fingolimod treatment was discontinued in 5 patients who developed a 
severe disease recurrence known as rebound phenomenon (Hatcher et al., 2016). Such a 
frequency is indeed clinically relevant and deserves more detailed investigation. Symptoms 
of recurrence usually start 4-12 weeks after drug withdrawal when lymphocytes reenter the 
circulation and the CNS. The mechanism underlying the rebound phenomenon is still 
unclear, but it has been speculated that different T cell subsets repopulate the circulating 
pool of immune cells with different kinetics. This is supported by the finding that in two 
patients with severe rebound after fingolimod withdrawal CD8+ T cells recovered more rapidly 
than the CD4+ and the CD19+ subsets (Hatcher et al., 2016). 
In an approach to investigate possible changes that occur in the immune system upon 
fingolimod withdrawal, the experimental autoimmune encephanomyelitis (EAE) model was 
performed in mice. Interestingly, T cells of mice under fingolimod withdrawal showed (1) a 
several-fold increase of S1P1 mRNA and (2) increased phospho-Akt signaling. Furthermore, 
compared to mice under continuous drug exposure, (3) an increased TH17/TH1 cell ratio, as 
analyzed in the spinal cord, and (4) reduced Treg cell function in lymph nodes was reported 
(Cavone et al., 2015). Functional rebound is often associated with treatment discontinuation 
and has also been described for various other immunosuppressive agents after abrupt dose 
reduction or withdrawal (Sueki et al., 2017). Clearly, further studies are warranted to pinpoint 
the type of immune cells responsible for the clinical symptoms after fingolimod withdrawal. 
 
7. Perspectives 
Fingolimod was the first S1PR modulator reported to have immunosuppressive activity and it 
is so far the only one that was approved for clinical use. However, fingolimod is a nonspecific 
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S1PR agonist and therefore new functionally related compounds have been developed, 
which better discriminate between the various S1PR subtypes and hence are expected to 
have improved efficacy and tolerability. These include the S1P1 selective compounds KRP-
203, ponesimod and cenerimod, the S1P1+5 selective siponimod and ozanimod, and the 
S1P1+4+5 selective amiselimod and etrosimod. Due to their higher selectivity, these new drug 
developments hold great promise for clinical benefit in a broad range of inflammatory and 
autoimmune diseases. 
On the other hand, for cancer therapy, the S1P1-dependent immunosuppressive effect of 
fingolimod is supposed to be counterproductive and therefore numerous preclinical 
investigations have focused on S1PR-independent (off-target) effects. In addition to 
fingolimod, several new formulations with improved tumor-targeting properties have been 
tested, all of them achieved measurable cytotoxic effects only at high concentrations in the 
µM range. Remarkably, to achieve anti-tumor effects in vivo doses of 10 mg/kg fingolimod 
per day were used, which is far beyond the dose of 0.5-1.25 mg per day at which adverse 
events already occur in patients treated for multiple sclerosis. We therefore conclude that 
fingolimod and the currently available new formulations will fail to achieve clinical responses 
in cancer patients at tolerable doses. 
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Table 1: Pharmacokinetic parameters of fingolimod 
 
PK parameters Values 
Dosing 0.5 mg daily p.o. 
Bioavailablity 93% 
Absorption Slow, high, food independent 
Metabolism Liver: by CYP4F2 
Elimination Renal, 81% 
Bound in plasma 99.7%  (mainly to albumin) 
Blood clearance Low, (6.3 L/h) 
Distribution volume 20 L/kg 
Half-live 6 - 9 days 
Max. plasma conc. 12-16 hours 
Steady state after 1-2 months 
Drug interactions Ketoconazole 
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Table 2: Selected adverse events reported from patients with relapsing-remitting MS treated 
with 0.5 mg fingolimod daily for 24 months 
 
Event* No. of patients 
fingolimod (N = 358) 
vs. placebo (N=355) 
Remarks 
Lymphopenia 27 (8%) vs. 0 After one month, peripheral blood 
lymphocyte counts dropped by an 
average of 75 %. This is an indication 
for a positive biological response and 
was not reported as adverse event. 
Lymphopenia as a complication was 
defined as less than 0.2 x 109 
lymphocytes per liter. 
Increased alanine amino 
transferase 
29 (8%) vs. 6 (2%)  
Increased gamma 
glutamyltransferase 
23 (6%) vs. 2 (14%)  
Herpes viral infections 30 (8%) vs. 19 (5%) Two fatal cases were reported from a 
previous study after treatment with 
1.25 mg fingolimod daily (Cohen et 
al., 2010) 
Hypertension 32 (9%) vs. 11 (3%) Small increases in systolic/diastolic 
blood pressure (~3/~1 mm Hg) after 
2-6 months (Camm et al., 2014) 
Bradycardia 5 (1%) vs. 1 (<0.5%) Mild to moderate with a mean 
decrease of 8 beats per minute in the 
first 6 h after treatment initiation. 
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Initial S1P1 agonism activates GIRK 
channels in atrial myocytes in the 
sinoatrial node, leading to 
hyperpolarization and reduction in 
excitability (Camm et al., 2014) 
First-degree AV block 17 (5%) vs. 7 (2%) In the first 6 h after treatment 
initiation, transient and asymptomatic. 
Same molecular effect on atrial 
myocytes in the AV node as 
described for bradycardia in the 
sinoatrial node (Camm et al., 2014).  
 
*Data were taken from Calabresi et al (Calabresi et al., 2014) based on the FREEDOMS II 
study (ClinicalTrials.gov number NCT00355134). Only complications are listed which 
occurred more frequently than in the placebo group and comprised >1% of the treated 
patients. 
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Table 3: Fingolimod and novel S1PR modulators in clinical studies 
 
Compound 
name 
S1PR 
profile 
approved Phase 3 Phase 2 Phase 1 
Fingolimod 
(FTY720) 
 
S1P1,3,4,5 RRMS PPMS Stroke 
Uveitis 
Schizophrenia 
ALS 
Rett’s 
syndrome 
KRP-203 
 
 
S1P1   UC (terminated) 
SLE 
(terminated) 
 
Ponesimod  
(ACT-128800) 
 
S1P1   RRMS 
Psoriasis 
Graft rejection 
 
 
Cenerimod 
(ACT-334441) 
 
S1P1   SLE  
Siponimod 
(BAF312) 
 
S1P1+5  SPMS RRMS 
Dermatomyositis 
Polymyositis 
 
Ozanimod 
(RPC-1063) 
 
S1P1+5  RRMS 
UC 
Crohn’s disease  
Amiselimod 
(MT-1303) 
 
S1P1,4,5   RRMS 
Crohn’s disease 
Psoriasis 
SLE 
Etrasimod 
(APD334) 
 
S1P1,4,5   UC  
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ALS, amyotrophic lateral sclerosis; PPMS, primary progressive multiple sclerosis ; RRMS, 
relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis ; SLE, 
systemic lupus erythematosus ; UC, ulcerative colitis.  
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